Ashley Gallagher is an editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
FDA Grants Breakthrough Therapy Designation to NVL-520 for ROS1-Positive NSCLC
February 28th 2024NVL-520 is a novel brain-penetrant ROS1-selective TKI being investigated for ROS1-positive metastatic non–small cell lung cancer in patients who have previously been treated with 2 or more ROS1 TKIs.
Read More
FDA Accepts Supplemental New Drug Application for Adagrasib for Colorectal Cancer
February 26th 2024The sNDA was based on results from the KRYSTAL-1 study, evaluating the drug alone or in combination with other anti-cancer therapies in those with advanced solid tumors who have KRASG12C mutations.
Read More
Telehealth Tool Shows 50% Reduction in Cardiovascular Hospital Readmissions
February 13th 2024Cardiac Solutions, a physician-owned practice specializing in personalized treatment plans, used RevUp Remote Patient Monitoring and Chronic Care Management to achieve these cardiovascular readmission rates.
Read More
Biosimilar Adalimumab, Etanercept Have Equivalent Effectiveness to Reference Drugs Over 48 Months
February 9th 2024The levels of disease activity after 6 months of tumor necrosis factor-α inhibitors could help predict the response to therapy at 4 years for those who have long-standing rheumatoid arthritis.
Read More